Novavax Reports Positive Preclinical Results for Pandemic Influenza VLP Vaccine Candidate
Novavax (Rockville, MD) has achieved favorable preclinical results for a new pandemic influenza virus-like particle (VLP) vaccine candidate that provided protection against several H5N1 virus strains.
Novavax (Rockville, MD) has achieved favorable preclinical results for a new pandemic influenza virus-like particle (VLP) vaccine candidate that provided protection against several H5N1 virus strains.
Results of a study conducted by a research group at the University of Hong Kong, through a collaboration with Novavax, showed 100% survival of mice immunized with this H5N1 VLP vaccine candidate. The H5N1 VLP contains three proteins—hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1)—which are considered important for inducing protection against influenza infection and severe disease.
This new influenza VLP, which was constructed and produced at Novavax, was designed to provide broad protection against several clades (or strains) of H5N1 avian influenza. The HA surface protein of this new VLP was modified to include the protein building blocks from several different H5N1 strains. This resulted in an immune response against several different H5N1 strains and may be a new approach to making broadly protective influenza vaccines. The study suggested that Novavax's recombinant VLP technology may be used for development of a vaccine capable of inducing broad cross protection against a variety of strains with pandemic potential without the use of an adjuvant.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
